---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018091"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-10-15T23:59:59+00:00"
generated_at: "2026-05-17T03:43:52.930005+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics raises $2.5M in registered direct offering and warrant issuance

## Summary
- Gross proceeds of $2.5M from sale of 3,125,000 ADSs at $0.80 per ADS; Ladenburg Thalmann as placement agent.
- Concurrent private placement: Series E (5-year) and Series F (30-month) warrants to purchase up to 3.125M ADSs each at $0.98 exercise price; exercisable upon shareholder approval.
- Proceeds to fund working capital, general corporate purposes, and R&D; includes generating data on ADC payload AKTX-101 for SITC meeting.
- Offering expected to close on or about October 16, 2025, subject to customary closing conditions.

## SEC filing metadata
- accession: 0001493152-25-018091
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315225018091/0001493152-25-018091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315225018091/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018091
- JSON: https://secwatch.observer/filing/0001493152-25-018091.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.